Imnovid is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow). It is used in combination with bortezomib (another cancer medicine) and dexamethasone (an anti\-inflammatory medicine) in adults who have received at least one treatment including lenalidomide (another cancer medicine). It is also used in combination with dexamethasone in adults who have received at least two prior therapies, including both lenalidomide and bortezomib, and whose disease has worsened. Imnovid contains the active substance pomalidomide. Multiple myeloma is rare, and Imnovid was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 October 2009\. Further information on the orphan designation can be found on [ema.europa.eu/medicines/human/orphan\-designations/EU309672](/en/medicines/human/orphan-designations/eu-3-09-672).
Therapeutic Indication
Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Therapeutic Area (MeSH)
ATC Code
L04AX06
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Pomalidomide | N/A | Pomalidomide |
EMA Name
Imnovid (previously Pomalidomide Celgene)
Medicine Name
Imnovid (previously Pomalidomide Celgene)
Aliases
N/ANo risk management plan link.
